Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 729-734

  Auvin, Stéphane ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

Antiepileptic drugs; Myoclonic epilepsy; Myoclonic seizure

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; FOLIC ACID; LAMOTRIGINE; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABSENCE; ADD ON THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; HUMAN; MONOTHERAPY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; TENDON REFLEX; TERATOGENICITY; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 38149098445     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Aliberti V, Grunewald RA, Panayiotopoulos CP, et al. 1994. Focal electroencephalographic abnormalities in juvenile myoclonic epilepsy. Epilepsia, 35:297-301.
2. Andermann E, Andermann F, Meyvisch P, et al. 2005. Seizure control with levetiracetam in juvenile myoclonic epilepsies. Epilepsia, 46(Suppl 8):205.
3. Andermann F, Berkovic SF. 2001. Idiopathic generalized epilepsy with generalized and other seizures in adolescence. Epilepsia, 42:317-20.
4. Atakli D, Sozuer D, Atay T, et al. 1998. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure, 7:63-6.
5. Baruzzi A, Procaccianti G, Tinuper P, et al. 1998. Antiepileptic drug withdrawal in childhood in childhood epilepsies: preliminary results of a prospective study. In: Faienza C, Prati G eds. Diagnostic and therapeutic problems in pediatric epileptology. Amsterdam: Elsevier. p 117-23.
6. Biraben A, Allain H, Scarabin J, et al. 2000. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology, 55:1758.
7. Biton V, Bourgeois B. YTC/YTCE study investigators. 2005. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol, 62:1705-8.
8. Buchanan N. 1996. The use of lamotrigine in juvenile myoclonic epilepsy, Seizure, 5:149-51.
9. Carrazana E, Wheeler S. 2001. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology, 56:1424-5.
10. Czapinski PP, Czapinska EM. 2004. The effectiveness of levetiracetam in drug-resistant juvenile myoclonic epilepsy. Epilepsia, 45(Suppl 3):141.
11. Dasheiff RM, Ritaccio AL. 1993. Characterization of intractable juvenile myoclonic epilepsy: new perspectives on primarily generalized seizures. Seizure, 2:11-19.
12. Delgado-Escueta A, Enrile-Bascal F. 1984. Juvenile myoclonic epilepsy of Janz. Neurology, 34:285-94.
13. Engel J. 2001. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and terminology. Epilepsia, 42:1-8.
14. Fernando-Dongas MC, Radtke RA, VanLandingham KE, et al. 2000. Characteristics of valproic acid resistant juvenile myoclonic epilepsy. Seizure, 9:385-8.
15. Gelisse P, Genton P, Kuate C, et al. 2004. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia, 45:1282-6.
16. Gelisse P, Genton P, Thomas P, et al. 2001. Clinical factors of drug resistance injuvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry, 70:240-3.
17. Genton P, Gelisse P, Thomas P, et al. 2000. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology, 55:1106-9.
18. Gerike C, Picard F, Saint-Martin A, et al. 1999. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled open study. Epileptic Disord, 1: 159-65.
19. Grunewald RA, Chroni E, Panayiotopoulos CP. 1992. Delayed diagnosis of juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry, 55:497-9.
20. Hanaya R, Sasa M, Ujihara H, et al. 1998. Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res, 789:274-82.
21. Harding W, Jeavons J. 1992. Photosensitive epilepsy. In: Harding W, Jeavons J eds. London: MacKeith Press. p 125-50.
22. Herdon HJ, Jerman JC, Stean TO, et al. 1997. Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranes. Br J Pharmacol, 121:1687-91.
23. ILAE. 1989. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia, 30:389-99.
24. Janz D. 1985. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand, 72:449-59.
25. Karceski S, Morrell M, Carpenter D. 2001. The expert consensus guideline series: Treatment of epilepsy. Epilepsy Behav, 2:A1-50.
26. Karceski S, Morrell M, Carpenter D. 2005. Treatment of epilepsy in adults: expert opinion. Epilepsy Behav, 7:S1-64.
27. Karlovassitou-Koriari A, Alexiou D, Angelopoulos P, et al. 2002. Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy. J Neurol, 249:396-9.
28. Kito M, Maehara M, Wanatabe K. 1996. Mechanisms of T-type channel blockade by zonisamide. Seizure, 5:115-9.
29. Kleveland G, Engelsen B. 1998. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure, 7:31-8.
30. Kothare S, Valencia I, Khurana D, et al. 2004. Efficacy and tolerability of zonisamide in juvenile rayoclonic epilepsy. Epileptic Disord, 6:267-70.
31. Lancman ME, Asconape JJ, Penry JK. 1994. Clinical and EEG asymmetries in juvenile myoclonic epilepsy. Epilepsia, 35:302-6.
32. Lees G, Leach MJ. 1993. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res, 612:190-9.
33. Levisohn P, Holland K, Hulihan J, et al. 2003. Topirarnate versus valproate in patients with juvenile myoclonic epilepsy. Epilepsia, 44:267-8.
34. Loiseau P, Duche B. 1990. Epilepsie myoclonique juvenile. Rev Neurol, 146:719-25.
35. Lynch BA, Lambeng N, Nocka K, et al. 2004. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA, 101:9861-6.
36. Mohanraj R, Brodie M. 2005. Pharmacological outcomes in newly diagnosed epilepsy. Epilepsy Behav, 6:382-7.
37. Morris G, Hammer A, Kustra R, et al. 2004. lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav, 5:509-21.
38. Nicolson A, Appelton R, Chadwick D, et al. 2004. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry, 75:75-9.
39. Obeid T, Panayiotopoulos CP. 1989. Clonazepam in juvenile myoclonic epilepsy. Epilepsia, 30:603-6.
40. Panagariya A, Sureka R, Ardana V. 2001. Juvenile myoclonic epilepsy - an experience from north western India. Acta Neurol Scand, 104:12-16.
41. Pisani F, Oteri G, Russo M, et al. 1999. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia, 40:1141-6.
42. Prasad A, Kuzniecky R, Knowlton R, et al. 2003. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol, 60:1100-5.
43. Resor SR, Resor LD. 2005. Levetiracetam monotherapy in the treatment of convulsive seizures in juvenile myoclonic epilepsy. Presented at the 54th Annual Meeting of the American Academy of Neurology, April 13-20,2002; Denver, CO.
44. Rudolph U, Crestani F, Benke D, et al. 1999. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature, 401:796-800.
45. Sharpe DV, Patel A, Fenichel GM, et al. 2005. Use of levetiracetam in juvenile myoclonic epilepsy [abstract]. Epilepsia, 46(Suppl 8):192.
46. Sousa Pda S, Araujo Fihlo G, Garzon E, et al. 2005. Topiramate for the treatment of juvenile myoclonic epilepsy. Arq Neuropsquiatr, 63:733-7.
47. Specchio L, Gambardella A, Giallonardo A, et al. 2006. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myclonic epilepsy. Epilepsy Res, 71:3 2-9.
48. Suzuki S, Kawakami K, Nishimura S, et al. 1992. Zonisamide blocks T-type channel in cultured neurons of rat cerebral cortex. Epilepsy Res, 12:21-7.
49. Szaflarski J. 2004. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav, 5:1024-6.
50. Thomas P, Valton L, Genton P. 2006. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain, 129:1281-92.
51. Usui N, Kotagal P, Matsumoto R, et al. 2005. Focal semiologic and electro-encephalographic features in patients with juvenile myoclonic epilepsy. Epilepsia, 46:1668-76.
52. Wheless JW, Clarke DF, Carpenter D. 2005. Treatment of pediatric epilepsy: expert opinion. Juvenile myoclonic epilepsy. J Child Neurol, 20:S42-3.
53. White H, Brown S, Woodhead J, et al. 2000. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia, 41:17-20.
54. Zona C, Ciotti MT, Avoli M. 1997. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett, 231:123-6.
55. + currents. Seizure, 10:279-86.